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Available online 23 January 2016AbstractMany evidences supported the suggestion that one of the reasons for the failure of immunosuppressant like Corticosteroides, Calcinurine
inhibitors and VitD3 in reestablishing skin immune tolerance is relying on inhibition of CCL22 expression from skin dendritic cells. Inhibition of
CCL22 decreases CD4þ CD25þ FoxP3þ regulatory T cells homing to macular area and reduces the suppression capacity of these cells that
make a sort of an imbalance between effector and regulatory T cells. Addition of CCL22 into the skin lesion from external sources could change
the ratio between effector and regulatory T cells which dramatically alter immune system and reestablish immune tolerance. This action can't be
established by the later immunosuppressant (e.g. corticosteroids and calcinurine inhibitors) alone which give CCL22 an important role in the
treatment of skin autoimmune and graft rejection diseases.
Copyright © 2016, Shanghai Hengrun Biomedical Technology Research Institute. Publishing services by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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CCL22 Chemokine is one of a group of heparin binding
proteins that induce migration and extravasation of chronically
activated Th2 cells into the skin. They produce their action
through binding to G protein-coupled receptor (CCR4) which in
turn increase intracellular Caþþ mobilization that affect
cytoskeleton-induced movement and increase the affinity of
targeted cells to adhesion molecules [1]. The adhesion mole-
cules E-selectin and intracellular adhesion molecule 1 (ICAM-
1) are greatly upregulated in the dermal post capillary venules by
cytokines released by skin resident antigen presenting cells likeAbbreviations: Tregs, regulatory T cells; CTL, cytotoxic T lymphocytes.
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produce activated T cell chemokines such as CCL22 on local
endothelium which resulted in recruitment of cutaneous leuko-
cyte antigenpositive (CLAþ)and chemokine receptor 4 positive
(CCR4þ)CD4þ CD25þ FoxP3þ regulatory T cells in antigen
non specific manner. In the skin, regulatory T cells encounter
their cognate antigen specific Langerhans dendritic cells. So,
they become activated and expanded to suppress activation and
proliferation of effector T cells. This pool of suppressive T cells
is prohibited in skin autoimmune diseases treated by Cortico-
steroides, Calcineurin inhibitors and VitD3 because they induce
IL-10 expression which in turn inhibit CCL22 production by
skin dendritic cells like Langerhans dendritic cells.
2. Macrophage derived chemokine (MDC)
CCL22 (Chemokine ligand 22) or Macrophage Derived
Chemokine “MDC”was discovered inmacrophages but it is also
produced by activated B lymphocytes and dendritic cells [2]. It
was also called “Stimulated T cell Chemotactic Protein-1”h Institute. Publishing services by Elsevier B.V. This is an open access article
.0/).
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1) or DC/B- CK (DC and B cell-derived chemokine) in mice
[2,4]. In human, CCL22 gene is found in a mini cluster in chro-
mosome 16q13 near gene of CCL17 (or, thymus and activation-
regulated chemokine: TARC) and their Chemokines have ho-
meostatic and inflammatory activity [5]. CCL22andCCL17bind
the same receptor (CCR4) and induce Caþþ mobilization and
chemo-attracting action on Th2 lymphocytes [6] with a prefer-
ential effect on CD4þ regulatory T lymphocytes [7].
CCL22 is constitutively expressed in dendritic cells, B
cells, and macrophages whereas NK cells, monocytes, and
CD4 lymphocytes express CCL22 after appropriate stimula-
tion [8]. Langerhans dendritic cells, which are skin-epidermis
populated immature dendritic cells, can also express CCL22
but only after maturation, however in mice it becomes the
most abundantly expressed gene [4,9]. Although it is difficult
to extrapolate these results to human, but langerhans dendritic
cells had already taken a great consideration as homeostatic
dendritic cells in human.
3. Langerhans dendritic cells and immune homeostasis in
the skin
When langerhans cells encounter antigen in the epidermis,
they drain to skin regional lymph node in response to CCL21
due to CCR7/CCL21 interaction. In lymph node, langerhansFig. 1. Tolerogenic Langerhans dendritic cells and Regulatory T cells interaction in
skin. One of them are resident in the skin and share the general marker (CD45RO
differentiated into Tregs in the regional lymph nodes by maturation signal from den
(CCR4þ, CLA) was suggested not to reach properly the organ specific autoimm
Vitamin D3 treatment because both of them suppress CCL22 production.Dendritic cells present antigen to naïve T cells to become
effector memory T Cells that express CLA (Cutaneus leuko-
cytes Antigen) and CCR4 (the receptor for CCL22) beside the
central memory T cells which reside in skin lymphoid organ
and express E-selectin (adhesion molecule) and CCR7(the
receptor for CCL21 and CCL19) Fig. 1. However, there are
another pathways for trafficking Langerhans dendritic cells at
steady state [10]. Upon second antigen encounter, effector
memory T Cells home to skin in antigen nonspecific manner
from regional skin lymph node through chemokine mediated
homing. On the other hand; langerhans cells expand also long
lived resident effector memory T cells [11].
While immunogenic action of langerhans cells had thor-
oughly been illustrated, their tolerogenic action is still being in
its infancy stage. Ralph. M. Steinman shared the Nobel Prize
in 2011 for his work on dendritic cells and their role in im-
munity. He uncovered the role of dendritic cells in peripheral
tolerance by applying antigen in absence of danger signal [12]
the work that gave the second wing for dendritic cells and
opened the door to know their role in homeostasis of the im-
mune system.
Julien Seneschal et al. (2012) illustrated the role of langer-
hans cells in maintaining immune homeostasis of the skin. The
results emphasize that langerhans cells induce the proliferation
of CD4þ CD25þFoxP3þCD127 skin resident regulatory T cells
which located in the epidermis. These cells suppressskin. This figure suggests that there are two sources of Tregs that populate the
þ) with skin resident effector T cells. The second are the naïve T cells that
dritic cells drained from skin. The second group of Tregs with general marker
une macular area in the skin under corticosteroids, calcineurin inhibitors and
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However, langerhans dendritic cells induce also expansion of
skin resident-effector memory T cells when they are co-
cultured with Candida albicans. So, Julien et al. suggested
that under steady state condition langerhans cells can keep
peripheral tolerance but they can also activate effector cells
against danger signals [13]. But, although many researches
were carried out in this field, It is remain to know in accurate
how to constantly programming tolerogenic langerhans den-
dritic cells.
4. Regulatory T cells populations in the skin
In the skin, there are skin resident memory T cells with
general marker (CLAþ,CD45Oþ,CCR4þ) 20 times more than
in blood [13,14], resident memory (CD4þCD25þFOXP3þ
CD127) regulatory T cells constitute 5% of these cells [15].
They are antigen specific and expanded by Langerhans den-
dritic cells which occur side by side with skin resident
CD45Oþ effector memory cells [13]. Beside skin resident
memory T cells, skin dendritic cells specially langerhans cells
present antigen to naïve T cells in draining lymph nodes.
Activated T cells resulted from antigen presentation got either
effector resident T cell markers (CCR4þ, CLAþ) or of central
memory T cell markers (CCR7, L-selectin) [11] Fig. 1. Other
type of Tregs are raised up in thymus by the process of
negative selection, in which T cells that recognize self-
antigens by T Cell Receptor with high affinity either died or
selected to survive as Tregs. This type of Tregs is called
natural Tregs and they are part of central tolerance, however
some T cells escape this process and may cause autoimmunity
[16].Fig. 2. Different factors regulate CCL22 or MDC (macrophage derived chemokine
dendritic induces 31-and 150-fold increase in production of CCL22 within 2 and 6
Neuropeptides; Calcitonin gene related peptide, PACAP: pituitary adenylate cyclas
mediator: Prostaglandin E2 and histamine. In general, all factors that increase cy
steroids and vitamin D3. While, UV effect on CCL22 production is a paradox.It was suggested that loss of peripheral tolerance in the skin
occurred in two steps: first, the induction phase in which the
effector-autoreactive T cells were stimulated and expanded by
CD4þ T cells. These cells circulate in the blood but with no
symptoms of autoimmunity whereas in the effector phase the
skin microenvironment became favor for escaping peripheral
tolerance [17] as in autoimmune microenvironment of non-
segmental vitiligo lesions in which down regulation of
CCL22 expression causes reduction in skin homing by func-
tional Tregs and resulted in imbalance between effector and
regulatory mechanisms [18].
According to their sources, the Tregs are either natural
Tregs or inducible Tregs. They both are FoxP3þ but were
differentiated by neuropilin-1 (Nrp-1), which is selectively
expressed on the surface of natural Tregs [19].
5. Major factors that regulate CCL22
Dendritic cells sense the antigens through various Pattern
recognition receptors (PRR) expressed by dendritic cells. In
response to this interaction, many cytokines and chemokines
are secreted. In 2001 Vulcano M. et al. revealed the great role
played by dendritic cells as the main source of CCL22 and
stated different factors that regulate their expression summa-
rized in Fig. 2. However in general, CCL22 is up regulated by
cyclic AMP- elevating agents.
Among these factors:5.1. CorticosteroidsCorticosteroids are immunosuppressant and anti-
inflammatory compounds have variable effects on immune) expression. They include Salmonella enterica Serovar Typhimurium infected
h post infection. They contain also Cytokines; IL-4, IFN-gamma beside IL-10,
e activating polypeptide and VIP: Vasoactive Intestinal Peptide. Inflammatory
clic AMP up-regulate MDC. Beside, Immunosuppressive agents like cortico-
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responses to antigens.
There are many evidences for the role corticosteroids in
suppression of CCL22 production by dendritic cells despite
of their ability to proliferate Th2 cells and regulatory T cells.
For example: Dexamethason down regulates CD83, IL-12
[20] in dendritic cells and induce production of IL-10 in T
cells [21] that inhibits their ability to produce CCL22.
Dexamethason also modify langerhans dendritic cells to up-
regulate TGF-beta and expand dermal regulatory T
CellsFOXP3þCD25þ [22]. Beside Dexamethason; Tacrolimus
and Cyclosporine also inhibit CCL22 production by Den-
dritic cells [20].5.2. Ultra violet BDifferent immunomodulation effects of UVB on keratino-
cytes were reviewed by (Brian Berman and Clay J. Cockerell,
2013). They characterize the membrane photo damage and
UVB phospholipids interaction that modify keratinocytes to
produce IL-10 and TNF-Alfa, which in turn generate tolero-
genic dendritic cells that expand TGF-beta producing-CD25þ
FoxP3þregulatory T cells [23].
Langerhans dendritic cells upon exposure to UVB became
unable to sensitize the body against selective antigen due to
DNA damage that modifies langerhans cells to have immu-
nosuppressive properties [24].
However, the effect of UVon the expression of CCL22 is a
paradox. While it may down regulate CCL22 indirectly
through IL-10 (produced by Tregs or keratinocytes), it may
causes CCL22 up regulation through IL-4, prostaglandin E2,
calcitonin gene related peptide, a melanocytes stimulating
hormone and platelet activating factor [20].5.3. Vitamin D3Vit.D3 differentiates dendritic cells to develop either
TGF-b secreting Foxp3þ Tregs or IL-10 secreting Tregs.
While Vit.D3 modifies dendritic cells to expand IL10-
producing Foxp3þ TRþ cells, it also modifies langerhans
dendritic cells to expand TGF-beta producing FoxP3þ regu-
latory T cells* [25]. Peleen et al. in 2011, reviewed different
roles played by Vit. D on dendritic cells, monocytes, NK
cells, T cells, NKT cells and B cells in peripheral immune
system. Like UVB, vitamin D3 down regulates different
markers on dendritic cells (CD86, CD80, and MHCII), it also
inhibits IL-12 production and up-regulates expression of IL-
10 and TNF-Alfa [26].
Vitamin D3 reduces production of CCL22 from LPS
inducededendritic cell maturation indirectly through produc-
tion of IL-10 which is known as a suppressor of CCL22
expression [20].5.4. Salmonella enterica Serovar Typhimurium BRD509In vitro studies of gene expression by bone marrow derived
dendritic cells showed that dendritic cells infectedbyBRD509Salmonella induces production of CCL22 by 31-
and 150-fold within 2 and 6 h post infection [27]. This mode
of expression could be tested in recruiting (CD4þ CD25þ
FoxP3þ) Tregs and others sub types in vitro and in vivo so as to
evaluate their capacity for recruiting such type of regulatory T
cells and also to further investigate Salmonella's genome and
proteome to specify the antigens that induce this maximum
expression of CCL22.
6. Model for study: non-segmental vitiligo
In vitiligo, the melanocytes antigens are carried by lang-
erhans dendritic cells and presented to naïve T cells in the
draining lymph nodes. The circulating cutaneous lymphocyte
antigen (CLA)-positive T cells are circulating memory cells in
the blood and have T cell receptors (TCRs) specific to antigens
of melanocytes previously encountered in the lymph nodes
such as: A2-melanA tetramere þ CTLs isolated from vitiligo
patients expressed high levels of CLA [17].
The immunohistochemistry showed infiltration of CD3þ T
cells in dermis and few in the epidermis. The double staining
of vitiligo biopsies by CD3þ and CD4þ showed that most of
CD3þ cells are also CD4þ. Whereas, CD3þ/CD8þ are pre-
sent in leading edge and lesional vitiligo skin and showing a
mixture of CD8þ and CD4þ T cells beside the appearance of
Th17 and Th1. However, double staining by CD3þ and
FoxP3þ showed a significantly reduced percentage of Tregs
among infiltrating T cells in non-lesional, perilesional and
lesional vitiligo skin compared to normal skin from healthy
adults [28].
In vitiligo perilesional skin, the increase in CD8þ T cells
was not accompanied by increase in Tregs (called Tregs
pausing). This significant reduction in Tregs is associated with
marked reduction in CCL22 expression by 43% in vitiligo
lesions comparing to controls, whereas the mode of expression
of CCL17 and CCL1 was normal which lead to suggestion that
a reduction in CCL22 expression is primarily responsible for
impaired homing of Tregs. Whereas functional Tregs are
abundant in the circulation [18]. So this support the hypothesis
looking at autoimmune diseases as an increase in CTL
comparing to Tregs and failure of Tregs to control CTL so as
to keep “peripheral tolerance”.
7. Discussion
The commonly used immunosuppressant like Glucocorti-
coids and Vitamin D3 can modify dendritic cells to expand
regulatory T cells which keep auto-reactive T cells in check.
However, they suppress CCL22 (the major cytokine respon-
sible for recruitment of regulatory T cells with CCR4þ,
CLAþ markers) to the affected area. Autoimmune diseases
like Vitiligo have poor lesional specific expression of CCL22
and so lower regulatory T cells infiltrating the affected area
than normal healthy skin. Theoretically, if we increase
expression of CCL22 in autoimmune lesions, we can rees-
tablish the balance between autoreactive and regulatory T cells
and stop progression of autoreactivity in the same way.
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the suggestion that “Local elevation of CCL22 could be a
treatment for organ specific autoimmune diseases”.
8. Diabetes type 1
Auto-reactive T cells against insulin-producing pancreatic
langerhans-islet are known in diabetes type-I. They are
blocked by antibodies [29] or transferred Tregs [30]and
showed good result in cessation of the progressive beta-cell
damage.
Montane. J et al., 2011 prevented marine auto-immune
diabetes by intra-pancreatic duct injection of double stranded
adeno-associated virus encoding CCL22 [31]. This resulted in
increase of CCL22 level in the pancreatic islet and recruited
endogenous regulatory T cells. The result of this experiment
was challenging because it resulted in prevention of b cells
destruction by auto-reactive T cells, sustained the protection
against auto-immune diabetes in NOD mice and delayed the
relapse of diabetes. Added to that, it increased the frequency
of TGF- b producing CD4þ regulatory T cells around the
pancreatic islet and decreased the frequency of circulating
CD8þ, IFN- g producing autoreactive T cells.
9. Bioinspired controlled release of CCL22
Siddharth Jhunjhunwala et al. (2012) designed a control
released vehicle for CCL22 and tested their device in many
mice models. The device was effectively able to delay rejec-
tion of allogenic cells transferred to the site previously
injected by CCL22MP. They found excessive migration of
regulatory T cells to the site of injection in response to CCL22
controlled release [32]. They finally concluded that the site-
specific attraction of Tregs leading to local immunomodula-
tion can be achieved in vivo using CCL22MP.
10. Conclusion
There are different strategies to deal with autoreactive T
cells. The first one is by depletion of the activated T cells,
which means any actively divided T cells. The second is by
expansion of regulatory T cells and recruit them through
Chemokines (like CCL22) to the specific macular area to do
area specific immunosuppression. The problem with this model
is in the dendritic cells stage of maturation because dendritic
cells express CCL22 only up on maturation whereas the
immunosuppressive therapies (like Corticosteroids and VitD3)
make them in an immature stage that inhibit CCl22 expression.
We need to knowmore about dendritic cells chemokines and
cytokines regulation in response to various sets of antigen to
choose the optimum path way for expansion and recruitment
of regulatory T cells so as to selectively inhibit auto reactive T
cells.
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